Oragenics received a notification from NYSE American on August 26, 2026, stating it is no longer in compliance with continued listing standards due to insufficient stockholders' equity. The company reported $3.7 million in equity at June 30, 2026, falling below the required $4 million threshold for firms with net losses in three of four recent years and the $6 million requirement for five consecutive years. Oragenics must submit a compliance plan by September 25, 2026, aiming to regain compliance by February 25, 2028. Failure to meet these deadlines or requirements may result in delisting procedures. The company's shares will continue trading under the symbol OGEN with a .BC designation indicating below-compliance status. Oragenics is a clinical-stage biopharmaceutical company developing brain-targeted therapeutics using an intranasal delivery platform.

Oragenics, Inc. announced the appointment of John Spencer as Chief Financial Officer, effective July 1, 2026. Spencer, previously the company's Senior Controller, will receive a base compensation of $200,000 and a $25,000 option award. Additionally, at the annual meeting held on June 29, 2026, shareholders approved a proposal authorizing the Board of Directors to enact a reverse stock split at any time within one year, with a ratio between 1-for-2 and 1-for-50. The meeting also resulted in the re-election of six directors and the ratification of Cherry Bekaert LLP as independent auditors. Oragenics, Inc. is a biotechnology company.